Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07620275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

StatusRecruiting
PhasePhase 1
Started2026-09-03
View on ClinicalTrials.gov ↗

Amendment history

2026-09-13
Study Status v2
Trial started: 2026-09-03 (last estimated 2026-09-10)
Start dateestimated 2026-09-10→confirmed 2026-09-03
2026-08-31
Study Status, Eligibility v1
Start date2026-06-10→2026-09-10
Eligibility criteria-50 characters
[...] r autologous HSCT within 3 months prior to KSVCBD infusion. Solitary extramedullary soft tissue plasmacytoma. Diagnosis of plasma cell leukemia, Waldenström's macroglobul [...]
2026-05-27
Original filing
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) multiple myeloma(MM) expressing CD19 and/or BCMA.
Trial Details
NCT Number NCT07620275
Lead Sponsor Chinese PLA General Hospital
Conditions Multiple Myeloma
Enrollment 9 participants
Start Date 2026-09-03
Primary Completion 2028-12-15 (estimated)
Study Completion 2029-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-15